Dr. Pedro Dorado is currently an Associate Professor at the University of Extremadura (UEX, Spain). He completed his Ph.D. in 2003, receiving both the "European Doctor” distinction and the University’s Doctoral Thesis Award. His professional trajectory includes predoctoral research at the UEX (1999–2003), teaching as an Auxiliary Professor at the University of Beira Interior in Portugal (UBI, 2003–2005), and postdoctoral research through the national competitive "Miguel Servet" Program (2007–2013). Dr. Dorado is a senior researcher at the University Institute of Biosanitary Research of Extremadura (INUBE). His research focuses on clinical pharmacology, pharmacogenetics, and the personalization of drug treatments. He has participated in 25 research projects, around 90 scientific articles, three book chapters, and more than 160 contributions to conferences and seminars. His international research experience includes predoctoral and postdoctoral stays at institutions such as the Karolinska Institutet (Sweden), Medical University of Debrecen (Hungary), UBI (Portugal), and the Universidad Autónoma Metropolitana (Mexico). He has also contributed to postgraduate education in Spain and Latin America, teaching in master’s programs and professional development courses at institutions such as the Universidad de San Marcos (Peru) and Universidad Nacional Autónoma de México (UNAM). He has supervised 12 Ph.D. dissertations and over 70 master’s and undergraduate theses.
Dr. Adrián Llerena-Ruiz received his M.D. degree in Medicine and Surgery and Ph.D. in Clinical Pharmacology/Pharmacogenetics from the University of Extremadura, Spain, in 1988 prior to his Postdoc in Clinical Pharmacogenetics at Karolinska Institute Department of Clinical Pharmacology (1989–1992/95). Currently, he is working as the Director of Clinical Research Center in Extremadura University Hospital and Medical School. He has successfully completed his administrative responsibilities as Vicedean of the Faculty of Medicine, Rectorate Office for Cooperation Development, and currently is a member of Pharmacogenomics Working Party at European Medicines Agency EMA for his third term (2010–). His research has included Clinical Pharmacogenetics and Psychopharmacology. Based on this research and fellowship training, he has received several awards and honors, such as the Latino American Association of National Societies of Pharmacology ALF Award for personal contribution to the development of Pharmacogenomics in Latin America (Havana LATINFARMA 2013). Currently, he is President of the Spanish Society of Pharmacogenetics and Pharmacogenomics, and in the past, he was Vice President of the Spanish Society of Clinical Pharmacology, Founder and former Vice President of the European Society of Pharmacogenetics and Theranostics (ESPT), and founder and Coordinator of the Iberoamerican Network of Pharmacogenetics and Pharmacogenomics RIBEF (2006–).
